Abbott Laboratories Stock News

The latest FDA approval is set to augment Abbott's (ABT) Neuromodulation arm, which is having a hard time amid the COVID spell due to its elective nature of business.

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

Shares of Abbott Laboratories shed 2.35% to $135.77 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow

ABBOTT PARK, Ill., Jan. 4, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2021 financial results on Wednesday, Jan. 26, 2022, before the market opens.

Dublin, Jan. 04, 2022 (GLOBE NEWSWIRE) -- The "Antifungal Drug Market Research Report by Infection Type, Type, Form, Therapeutic Indications, and Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com''s offering. The Global Antifungal Drug Market size was estimated at USD 12.55 billion in 2020, is expected to reach USD 13.26 billion in 2021, and projected to grow at a CAGR of 6.00% reaching USD 17.81 billion by 2026. Market Statistics

In the latest trading session, Abbott (ABT) closed at $139.04, marking a -1.21% move from the previous day.

Riding on current business growth and bullish near-term prospects, Abbott (ABT) is worth investing in for now.

Abbott Laboratories (ABT) shares closed today at 1.1% below its 52 week high of $142.60, giving the company a market cap of $249B. The stock is currently up 30.9% year-to-date, up 32.3% over the past 12 months, and up 302.7% over the past five years. This week, the Dow Jones Industrial Average rose 2.1%, and the S&P 500 rose 2.1%. Trading Activity Trading volume this week was 49.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 73.0% The company's stock price performance over the past 12 months beats the peer average by 72.1% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 9.7% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Could these dividend stocks be big winners in the new year?

The Zacks Analyst Blog Highlights: Apple, Abbott Laboratories, Infosys, General Motors and NIO

Dublin, Dec. 30, 2021 (GLOBE NEWSWIRE) -- The "Lung Cancer Diagnostics Market Size, Share, Global Forecast 2022-2027, Industry Trends, Impact of COVID-19, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com''s offering. Globally, lung cancer occurs when cells divide in the lungs uncontrollably - further causing tumours to grow, which reduces a person''s ability to breathe and spread to other parts of the body.

Abbott Laboratories (ABT) shares closed today at 1.0% below its 52 week high of $142.60, giving the company a market cap of $248B. The stock is currently up 30.3% year-to-date, up 32.3% over the past 12 months, and up 301.6% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 43.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 71.0% The company's stock price performance over the past 12 months beats the peer average by 64.9% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 9.5% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

You don't need to sacrifice a good yield for safety.

Abbott (ABT) registers strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.

Abbott Laboratories (ABT) shares closed today at 1.5% below its 52 week high of $142.60, giving the company a market cap of $250B. The stock is currently up 31.2% year-to-date, up 32.6% over the past 12 months, and up 300.4% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 36.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 71.4% The company's stock price performance over the past 12 months beats the peer average by 58.9% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 10.3% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.